Association of <i>eNOS</i> and <i>ACE</i> gene polymorphisms and plasma nitric oxide with risk of non‐small cell lung cancer in South India

Peddireddy, Vidyullatha; Badabagni, Siva Prasad; Gundimeda, Sandhya Devi; Mundluru, Hema Prasad

doi:10.1111/crj.12517

Cited by 18 publications

(14 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent two decades, polymorphisms of eNOS gene have gained attention for susceptibility of tumorigenesis or carcinogenesis, as well as cancer invasion and metastasis. Several studies focused on the associations of its three major polymorphisms, namely G894T, T-786C and VNTR 4a/b, and different cancers, such as bladder 13 - 15 , 22 , colorectum 14 , 15 , 23 , breast 11 , 13 , 14 , 24 - 26 , prostate 14 , 17 , 27 - 33 , stomach 14 , 34 , lung 35 - 41 , liver 10 , 14 , 42 , gallbladder 43 , pancreas 44 , and others 14 , 45 - 47 . There were also different researches investigating correlation of eNOS polymorphisms and responsiveness of different therapies toward malignancies, such as chemotherapy, targeted therapy and radiotherapy 5 , 10 , 38 , 48 - 53 .…”

Section: Discussionmentioning

confidence: 99%

“…And yet, the answer was conflicting so far. One study showed that VNTR polymorphism was the culprit 35 , while another believed high expression of NOS was a favorable prognostic sign 40 . Moreover, Donnini et al also reports that NO and PGE2 exist cross-talk effects in EGFR-driven epithelial tumor cells and may as the better therapeutic strategies for cancer treatment 54 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan

Huang

Hsieh

et al. 2018

J. Cancer

View full text Add to dashboard Cite

EGFR mutation of Non-small cell lung cancers (NSCLC) was predominantly seen in Asian population and it was considered as a predictor of responsiveness. Eendothelial nitric oxide synthase (eNOS) plays a vital role in chronic inflammation and carcinogenesis. In this study, we aimed to explore the association between the genetic polymorphisms of eNOS (-786T/C and 894 G/T) and EGFR mutation in patients with lung adenocarcinoma. A total of 277 patients with diagnosed lung adenocarcinoma were recruited between years 2012 and 2015. All study subjects underwent the analysis of eNOS genetic variants (-786 T/C and 894 G/T) using real-time polymerase chain reaction (PCR) genotyping. Our results showed that, among the 277 patients, variant types (GT + TT) of eNOS 894 G/T polymorphism were significantly positively correlated with EGFR mutation type, specifically exon 19 in-frame deletion. With the subgroup of EGFR L858R mutation, variant genotypes (GT + TT) of eNOS 894 G/T were significantly associated with lymph node invasion. Moreover, in silico analysis indicated that eNOS 894 G/T altered the eNOS expression. In conclusion, our study showed that eNOS 894 G/T variants were significantly associated with EGFR mutation types of lung adenocarcinoma, specifically exon 19 in-frame deletion. This may be utilized as a prediction of tumor invasiveness and therapy responsiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan

Huang

Hsieh

et al. 2018

J. Cancer

View full text Add to dashboard Cite

show abstract

“…For example, Han et al (14)found that upregulation of ACE in mice increased the risk of laryngeal cancer. Peddiredy, Vidyullatha and others (15) found that in India, the diversity of ACE and eNOS genes increased the risk of non-small cell lung cancer, and the expression of ACE in lung cancer tissues was lower than that of tissue adjacent to cancer tissues. It is just like Blánaid M Hicks and others (16) found that the use of ACEIs is associated with an increased risk of lung cancer, and this correlation is particularly signi cant in people who have used ACEIs for more than 5 years.…”

Section: Discussionmentioning

confidence: 99%

Effect of miR-181b on the biological characteristics and clinical drug resistance of small cell lung cancer by targeting gene ACE2

Liu

Han

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective To clarify the effect of miR-181b on the biological function of SCLC, to detect and verify its downstream target gene ACE2, and to explore the effect of clinical resistance on SCLC in order to find new specific diagnostic markers and therapeutic targets.Methods 1. Collect blood samples from 30 SCLC patients and 30 normal persons in our department from 2017 to 2019 to detect the expression level of miR-181b; 2. Detect the expression level of miR-181b in SCLC cells by RT-PCR, and Screening of downstream target genes used by gene chip, verification with luciferase and Western Blot; 3. Collect the general data of 30 SCLC patients and 30 healthy people (control group)，the patients were diagnosed by pathology and undergoing EC protocol in the Department of Thoracic Surgery and Oncology of our hospital to detect the expression level of mir-181b in different periods; 4. In the SCLC cell line and the SCLC mouse model constructed, different concentrations of EC chemotherapy and ACEI drugs were administered to detect the sensitivity of drug resistance and non-drug resistance.Results 1. The expression level of miR-181b in SCLC patients was lower than normal people; 2. The expression level of miR-181b in SCLC cell lines was lower than normal cells; ACE2 was verified as a downstream target of miR-181b by gene chip screening; 3. miR-181b is low-expressed in SCLC patients, first-line chemotherapy can promote its recovery, but cannot repair to normal levels, and miR-181b has a certain effect on SCLC chemotherapy sensitivity; 4. miR-181b can enhance the drug sensitivity of SCLC drug-resistant cells, the application of ACEI should increase the risk of SCLC drug-resistant.Conclusion 1. miR-181b has a low expression level in SCLC, and it can directly target the gene ACE2 to affect the biological characteristics of SCLC; 2. miR-181b is lowly expressed in SCLC patients, and first-line chemotherapy can promote it recovery, but cannot repair to normal levels, and ACEI drugs can increase the risk of SCLC drug-resistant.

show abstract

“…24 Contrastingly, Peddireddy et al showed a correlation between non-small cell lung cancer and intron 4 27 bp repeat polymorphism in patients with the a/a genotype. 26 Fujimoto et al 27 reported that NOS activity was significantly higher in patients with lung adenocarcinoma than in normal subjects, and most of the total NOS activity in their samples was mediated by structural eNOS. Shaul et al 28 suggested that eNOS may play a role in the development and differentiation of both normal and neoplastic airway epithelium.…”

Section: Enos Gene G894t Genotypementioning

confidence: 99%

The role of endothelial nitric oxide synthase gene polymorphisms in patients with lung cancer

Koçer

Benlier

Balcı

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Globally, lung cancer is the most common type of cancer. 1 The incidence of lung cancer ranges between 27.8 and 47.4 per 100 000 in men and between 11.1 and 18.6 per 100 000 in women. 2 Its etiology includes cigarette smoking, occupational exposures to asbestos and nickel, genetic predisposition and various lung diseases. 3 Several studies have demonstrated that the genetic basis of lung cancer involves mutations in the tumor suppressor genes p53 and Rb, D12S0134, D6S474 and D19S246 microsatellite markers, checkpoint kinase 2 gene mutations in the epidermal growth factor receptor, glutathione-S-transferase (GST) P1, myeloperoxidase (MPO), cytochrome P450 (CYP)1A1, cyclooxygenase 8473T > C and TGF-beta1 −509C > T and 869T > C polymorphisms, endothelial nitric oxide (NO) synthase gene intron 4, 27 bp repeat polymorphism. 4-6

show abstract

Association of eNOS and ACE gene polymorphisms and plasma nitric oxide with risk of non‐small cell lung cancer in South India

Abstract: We report for the first time that polymorphisms in the eNOS "A/A" (homozygous mutant) and ACE "I/D" genotypes might contribute to the increased risk of NSCLC in the South Indian population.

Cited by 18 publications

References 60 publications

Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan

Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan

Effect of miR-181b on the biological characteristics and clinical drug resistance of small cell lung cancer by targeting gene ACE2

The role of endothelial nitric oxide synthase gene polymorphisms in patients with lung cancer

Contact Info

Product

Resources

About